$0.01
(Market cap
$3 Mln
Recently Viewed
Clear AllMarket cap
$3 Mln
Revenue (TTM)
$25 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-29 Mln
ROE
-21 %
ROCE
-- %
Industry P/E
24.57
EV/EBITDA
-0.7
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
28,015,400
CFO
$-245.04 Mln
EBITDA
$-272.35 Mln
Net Profit
$-258.29 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Novan (NOVN)
| -97.6 | -30.6 | -91.7 | -98.0 | -81.0 | -73.5 | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
Novan (NOVN)
| -65.0 | -48.7 | -74.3 | 280.7 | -80.2 | -84.4 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Novan (NOVN)
|
0.0 | 2.6 | 24.7 | 1.0 | -144.2 | -- | -- | 5.1 |
| 12.4 | 3,993.9 | 3,018.8 | 72.1 | 12.6 | -80 | 56.9 | 105.4 | |
| 40.9 | 5,228.7 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.2 | 14.1 | |
| 187.9 | 9,667.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 109.5 | |
| 73.8 | 14,879.0 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.1 | 4,910.2 | 761.4 | 99.7 | 7.3 | 15 | 56.3 | 7.6 | |
| 22.4 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.1 | 7,186.6 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.5 | 1.0 | |
| 226.6 | 4,622.8 | 268.1 | 124.5 | 60.0 | 13.5 | 37.8 | 4.4 | |
| 61.4 | 3,667.1 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.0 |
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris;... SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, Novan, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
Pres, CEO & Chairwoman
Ms. Paula Brown Stafford M.P.H.
Pres, CEO & Chairwoman
Ms. Paula Brown Stafford M.P.H.
Headquarters
Durham, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Novan Inc (NOVN) is $0.03 (NASDAQ) as of 26-Sep-2023 09:30 EDT. Novan Inc (NOVN) has given a return of -80.99% in the last 3 years.
Since, TTM earnings of Novan Inc (NOVN) is negative, P/E ratio is not available.
The P/B ratio of Novan Inc (NOVN) is 5.10 times as on 26-Sep-2023, a 11 discount to its peers’ median range of 5.70 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Novan Inc (NOVN) are Rs -- and Rs -- as of 25-Apr-2026.
Novan Inc (NOVN) has a market capitalisation of $ 3 Mln as on 26-Sep-2023. As per SEBI classification, it is a company.
Before investing in Novan Inc (NOVN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.